Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)
Status:
Terminated
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
DTGM belongs to a new generation of drugs designed to target leukemic cells. To achieve this,
DTGM takes advantage of the ability of naturally-produced growth factor (GM,
granulocyte-macrophage stimulating factor) to deliver a drug (diphtheria toxin) to cells;
preferably leukemic cells. It then attaches to the cells and allows the toxin to enter the
leukemic cells and destroy them.